Lazard Downgrades CombinatoRx (CRXX) to Hold
More News related to CRXX
- CombinatoRx Oncology Programs to Be Highlighted at ASH 2009
- CombinatoRx, Inc. (CRXX) and Neruomed Pharma Receive U.S. FDA Letter Regarding NDA for Exalgo
- FDA Extends NDA Review for Exalgo(TM) Extended-Release Tablets
- Unusual 11 Mid-Day Movers 11/16: SPEX, NLST, DRAM, XJT Higher; PARD, CRXX, CAEI, CHIO Lower
- Morning Movers 11/16: SPEX, NLST, XJT, NABI, KHD, IBKC, SPA Higher; PARD, CRXX, CAEI Lower
More News related to Downgrades
- Davenport Downgrades Nokia (NOK) to Neutral
- Sidoti & Co Downgrades Innophos Holdings (IPHS) to Neutral
- Sidoti & Co Downgrades Tyler Technologies (TYL) to Neutral
- China BAK (CBAK) Shares Tumble Amid Q4 Results, Roth Capital Downgrade
- Canaccord Adams Downgrades Micromet (MITI) to Hold
Lazard Capital downgrades CombinatoRx (Nasdaq: CRXX) from Buy to Hold.
CombinatoRx, Incorporated, a biopharmaceutical company, develops synergistic combinations of approved drugs, with a portfolio of product candidates in Phase II clinical development, using its proprietary combination high throughput screening (cHTS) technology.
Related Categories
DowngradesStocks Mentioned
-0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
